Hemorrhagic Shock
3
Pipeline Programs
4
Companies
4
Clinical Trials
1 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
U
LYSTEDAApproved
tranexamic acid
Unknown CompanyAntifibrinolytic Agent [EPC]oral2009
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Innogene KalbiotechSingapore - Singapore
1 program1
Hyperosmolar sodium lactatePhase 31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Arrowhead PharmaceuticalsTranexamic Acid
Innogene KalbiotechHyperosmolar sodium lactate
Arsenal BiosciencesResQFoam
City TherapeuticsGlutamine
Clinical Trials (4)
Total enrollment: 205 patients across 4 trials
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
Start: Mar 2015Est. completion: Jul 2024200 patients
Phase 3Completed
Efficacy, Safety of Solution Containing Hyperosmolar Sodium Lactate Infusion for Resuscitation of Patients With Hemorrhagic Shock
Start: Jul 2009Est. completion: Jan 2011
Phase 3Completed
REVIVE: Reducing Exsanguination Via In-Vivo Expandable Foam
Start: Aug 2025Est. completion: Dec 2026
N/ARecruiting
Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy
Start: Jan 2011Est. completion: Dec 20135 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 205 patients
4 companies competing in this space